Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study.

Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, Jaquish C, Douglas JA, Roy-Gagnon MH, Sack P, Naglieri R, Hines S, Horenstein RB, Chang YP, Post W, Ryan KA, Brereton NH, Pakyz RE, Sorkin J, Damcott CM, O'Connell JR, Mangano C, Corretti M, Vogel R, Herzog W, Weir MR, Peyser PA, Shuldiner AR.

Am Heart J. 2008 May;155(5):823-8. doi: 10.1016/j.ahj.2008.01.019. Epub 2008 Mar 5.

2.

Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study.

North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, MacCluer JW.

Am J Epidemiol. 2003 Feb 15;157(4):303-14.

PMID:
12578801
3.

Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study).

Shen H, Herzog W, Drolet M, Pakyz R, Newcomer S, Sack P, Karon H, Ryan KA, Zhao Y, Shi X, Mitchell BD, Shuldiner AR.

Am J Cardiol. 2009 Aug 15;104(4):606-12. doi: 10.1016/j.amjcard.2009.04.027. Epub 2009 Jun 21.

4.

Omega 6 fatty acids for the primary prevention of cardiovascular disease.

Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper L, Rees K.

Cochrane Database Syst Rev. 2015 Nov 16;(11):CD011094. doi: 10.1002/14651858.CD011094.pub2. Review.

PMID:
26571451
5.

Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.

Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, Kesmarky G, Czopf L, Toth K.

Drugs Aging. 2006;23(7):559-67.

PMID:
16930084
6.

Evidence for distinct genetic effects on obesity and lipid-related CVD risk factors in diabetic compared to nondiabetic American Indians: the Strong Heart Family Study.

North KE, MacCluer JW, Williams JT, Welty TK, Best LG, Lee ET, Fabsitz RR, Howard BV.

Diabetes Metab Res Rev. 2003 Mar-Apr;19(2):140-7.

PMID:
12673782
7.

Genetic effects on postprandial variations of inflammatory markers in healthy individuals.

Cheng YC, Kao WH, Mitchell BD, Sharrett AR, Ryan KA, Vogel RA, Shuldiner AR, Pollin TI.

Obesity (Silver Spring). 2010 Jul;18(7):1417-22. doi: 10.1038/oby.2009.416. Epub 2009 Nov 12.

8.

Do genetic variations alter the effects of exercise training on cardiovascular disease and can we identify the candidate variants now or in the future?

Hagberg JM.

J Appl Physiol (1985). 2011 Sep;111(3):916-28. doi: 10.1152/japplphysiol.00153.2011. Epub 2011 May 12. Review.

9.

Antiplatelet therapies: aspirin at the heart of new directions.

Bunimov N, Laneuville O.

Cardiovasc Hematol Disord Drug Targets. 2013 Dec;13(3):173-84.

PMID:
24479717
10.

Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease.

Fan L, Cao J, Liu L, Li X, Hu G, Hu Y, Zhu B.

Gerontology. 2013;59(2):122-31. doi: 10.1159/000342489. Epub 2012 Sep 28.

PMID:
23038044
11.

Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.

Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM.

Circulation. 2007 May 15;115(19):2490-6. Epub 2007 Apr 30.

12.

Antiplatelet effect of aspirin in patients with coronary artery disease.

Grove EL.

Dan Med J. 2012 Sep;59(9):B4506. Review.

PMID:
22951204
13.

Genetics and cardiovascular disease.

Acton RT, Go RC, Roseman JM.

Ethn Dis. 2004 Autumn;14(4):S2-8-16. Review.

PMID:
15724791
14.

Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study.

Roy-Gagnon MH, Weir MR, Sorkin JD, Ryan KA, Sack PA, Hines S, Bielak LF, Peyser PA, Post W, Mitchell BD, Shuldiner AR, Douglas JA.

J Hypertens. 2008 Apr;26(4):729-36. doi: 10.1097/HJH.0b013e3282f524b4.

15.

Dietary fibre for the primary prevention of cardiovascular disease.

Hartley L, May MD, Loveman E, Colquitt JL, Rees K.

Cochrane Database Syst Rev. 2016 Jan 7;(1):CD011472. doi: 10.1002/14651858.CD011472.pub2. Review.

PMID:
26758499
16.
17.

Qigong for the primary prevention of cardiovascular disease.

Hartley L, Lee MS, Kwong JS, Flowers N, Todkill D, Ernst E, Rees K.

Cochrane Database Syst Rev. 2015 Jun 11;(6):CD010390. doi: 10.1002/14651858.CD010390.pub2. Review.

PMID:
26068956
18.

Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2010 Dec;12(12):839-43. doi: 10.1097/GIM.0b013e3181f872c0.

PMID:
21042222
19.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

20.

Genetics of variation in HOMA-IR and cardiovascular risk factors in Mexican-Americans.

Voruganti VS, Lopez-Alvarenga JC, Nath SD, Rainwater DL, Bauer R, Cole SA, Maccluer JW, Blangero J, Comuzzie AG.

J Mol Med (Berl). 2008 Mar;86(3):303-11. doi: 10.1007/s00109-007-0273-3. Epub 2008 Jan 17.

PMID:
18204828

Supplemental Content

Support Center